Key facts
- This page summarizes Stephan Epinette Power's Form 3 filing for CONMED Corp (CNMD).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 15 May 2025, 09:57.
Stephan Epinette Power - 24 Feb 2025 Form 3 Insider Report for CONMED Corp (CNMD)
- Reporting relationship
- VP GM International
- Issuer ticker
- CNMD
- Reported as of
- 24 Feb 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 15 May 2025, 09:57:36 UTC
- Next SEC filing
- 15 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Thomas Fistek for Stephan Epinette by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephan Epinette Power filed Form 3 for CONMED Corp (CNMD) on 15 May 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001507941
Primary reporting owner
Epinette Stephan
- Relationship
- VP GM International
- Address
- C/O CONMED CORPORATION, 11311 CONCEPT BOULEVARD, LARGO
- Signature
- /s/Thomas Fistek for Stephan Epinette by Power of Attorney
- Signature date
- 13 May 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNMD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,510
- Date
- 24 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNMD
holding
Derivative
Options To Purchase Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $96.16
- Footnotes
- F2
CNMD
holding
Derivative
Options To Purchase Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $79.95
- Footnotes
- F2
CNMD
holding
Derivative
RSUs (Restricted Stock Units)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,375
- Exercise price
- $0.000000
- Footnotes
- F3
CNMD
holding
Derivative
RSUs (Restricted Stock Units)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,000
- Exercise price
- $0.000000
- Footnotes
- F3
CNMD
holding
Derivative
RSUs (Restricted Stock Units)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 24 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,500
- Exercise price
- $0.000000
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Stephan Epinette became an officer of CONMED Corporation on February 24, 2025. Exhibit index Power of Attorney (public).
Footnote F2
The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period
Footnote F3
Represents the settlement of vested restricted stock units (RSUs) with the delivery of shares of common stock, subject to withholding for taxes. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period.